-
-
-
-
-
-
-
Menlo Therapeutics (MNLO) PT Raised to $2.50 at H.C. Wainwright
-
-
-
-
-
-
-
Menlo Therapeutics Announces Results from Phase 2 Trial of Serlopitant in Patients with Chronic Pruritus of Unknown Origin
-
-
-
-
-
-
-
Menlo Therapeutics CEO to Participate in Fireside Chat at the Piper Jaffray 31st Annual Healthcare Conference
-
-
-
-
-
-
-
Menlo Therapeutics to Host Investor Day October 29, 2019
-
-
-
-
-
-
-
Menlo Therapeutics Reports Second Quarter 2019 Financial Results and Provides Program Updates Including Accelerated Timeline for Upcoming Clinical Data
-
-
-
-
-
-
-
Menlo Therapeutics Announces Publication of Serlopitant Phase 2 Data for the Treatment of Pruritus Associated with Prurigo Nodularis
-
-
-
-
-
-
-
Report: Developing Opportunities within Liberty TripAdvisor, Chanticleer, Retrophin, Menlo Therapeutics, Shire plc, and Matthews International — Future Expectations, Projections Moving into 2018
-
1,197,452 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

